SAN DIEGO -- AXS-12 (reboxetine), an investigational treatment for narcolepsy, reduced weekly cataplexy attacks and in some cases provided complete remission, the phase III SYMPHONY study showed. From ...

Narcolepsy, with or without cataplexy, can have a substantial detrimental effect on well-being and quality of life. Because there is no cure for this condition, current treatments aim to improve ...

Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial ...

If you or someone in your household has narcolepsy, you know how much this condition can affect daily life. People with narcolepsy have fragmented nighttime sleep and extreme sleepiness during the day ...